SCHEMBL23705437

SCHEMBL23705437

CCSc1cc(C(=O)OC)ccc1CN=[N+]=[N-]

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.43
KDM4E B2RXH2 7/20 0.43
ALDH1A1 P00352 5/20 0.43
HSD17B10 Q99714 4/20 0.43
HPGD P15428 4/20 0.43
TP53 P04637 2/20 0.43
LMNA P02545 2/20 0.43
ALOX15 P16050 2/20 0.43
KMT2A Q03164 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
MEN1 O00255 1/20 0.43
ALOX12 P18054 1/20 0.43
HTT P42858 1/20 0.43
TSHR P16473 1/20 0.38
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA7 P43166 1/20 0.37
XDH P47989 1/20 0.37
CA9 Q16790 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15862099 0.83 CA1 (0.44) MAPTKDM4EALDH1A1HSD17B10HPGD
SCHEMBL14845579 0.79 MAPT (0.49) MAPTKDM4EALDH1A1HPGDLMNA
SCHEMBL13949540 0.79 DPP4 (0.43) MAPTKDM4EALDH1A1HSD17B10HPGD
SCHEMBL23704834 0.79 KDM4E (0.49) MAPTKDM4EALDH1A1HSD17B10HPGD
SCHEMBL23715374 0.79 MAPT (0.49) MAPTKDM4EALDH1A1HSD17B10HPGD
SCHEMBL26524175 0.76 NOTUM (0.47) MAPTKDM4EALDH1A1HSD17B10HPGD
SCHEMBL23704973 0.76 HDAC3 (0.36) MAPTKDM4EALDH1A1HSD17B10HPGD
SCHEMBL30460582 0.74 DPP4 (0.39) MAPTKDM4EALDH1A1HSD17B10HPGD
SCHEMBL23705374 0.74 ALDH1A1 (0.53) MAPTKDM4EALDH1A1HSD17B10HPGD
SCHEMBL16687506 0.73 KDM4E (0.38) MAPTKDM4EALDH1A1HSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
CN-115484948-A Compound and use thereof 福宏治疗公司 2022-12-16 CN disclosed
EP-4096657-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2022-12-07 EP disclosed
WO-2021155316-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149414-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB MAPT 2074/4885KDM4E 1848/4885ALDH1A1 2571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.